News
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.
Clinical Trials Arena on MSN18h
Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmedEli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback